Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 11/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.53 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8543514 | 1.00 | MAPKAPK2 (0.54) | MAPKAPK2SIRT1SIRT2SIRT3KIF11 | |
| SCHEMBL8545321 | 1.00 | MAPKAPK2 (0.54) | MAPKAPK2SIRT1SIRT2SIRT3KIF11 | |
| SCHEMBL8543519 | 1.00 | MAPKAPK2 (0.54) | MAPKAPK2SIRT1SIRT2SIRT3KIF11 | |
| SCHEMBL8545315 | 1.00 | MAPKAPK2 (0.54) | MAPKAPK2SIRT1SIRT2SIRT3KIF11 | |
| SCHEMBL8858882 | 0.85 | MAPT (0.64) | SIRT1SIRT2SIRT3KIF11ALOX15 | |
| SCHEMBL8858890 | 0.85 | MAPT (0.64) | SIRT1SIRT2SIRT3KIF11ALOX15 | |
| SCHEMBL8858885 | 0.85 | MAPT (0.64) | SIRT1SIRT2SIRT3KIF11ALOX15 | |
| SCHEMBL8858868 | 0.85 | MAPT (0.64) | SIRT1SIRT2SIRT3KIF11ALOX15 | |
| SCHEMBL8858878 | 0.85 | MAPT (0.64) | SIRT1SIRT2SIRT3KIF11ALOX15 | |
| SCHEMBL10579158 | 0.81 | SLC6A4 (0.54) | MAPKAPK2SIRT1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105666-A1 | TRIAZABENZO (A)NAPHTHO(2,1,8-CDE) AZULENE COMPOUNDS. | LES LABORATOIRES SERVIER (FR) | 2010-04-29 | — | — | US | disclosed |
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | LES LABORATOIRES SERVIER (FR) | 2009-12-03 | — | — | US | disclosed |
| EP-0658557-B1 | Eburnane derivatives, processes for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1998-09-02 | — | — | EP | disclosed |
| EP-0658557-A1 | Eburnane derivatives, processes for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1995-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105666-A1 | TRIAZABENZO (A)NAPHTHO(2,1,8-CDE) AZULENE COMPOUNDS. | NR1I2, NR2E1, NR0B2 | MAPKAPK2 4639/4885SIRT1 3329/4885SIRT2 1800/4885 |
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | NLN, GAP43, SNCA | MAPKAPK2 1992/4885SIRT1 345/4885SIRT2 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.